Modality
Degrader
MOA
Anti-Aβ
Target
GIP-R
Pathway
Ferroptosis
ALSRBCeliac
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
~Aug 2019
→ ~Nov 2020
Phase 3
~Feb 2021
→ ~May 2022
NDA/BLA
Aug 2022
→ Jul 2029
NDA/BLACurrent
NCT04354265
2,160 pts·RB
2022-08→2029-07·Terminated
NCT03453479
2,926 pts·ALS
2024-02→TBD·Not yet recruiting
5,086 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-07-223.3y awayPh3 Readout· RB
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
NDA/BLA
Termina…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2029-07-22 · 3.3y away
RB
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04354265 | NDA/BLA | RB | Terminated | 2160 | MRD |
| NCT03453479 | NDA/BLA | ALS | Not yet recr... | 2926 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |